Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Soluble Neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors

Figure 1

Serum sN-CAD levels in control subjects and in all patients. Box plots representing the levels of soluble N-cadherin (sN-CAD) in the sera of 87 control subjects and 73 sarcoma patients. The significance of differences was determined using the Mann–Whitney U test (p <0.001). The levels of sN-CAD in the control subjects were less than 500 ng/ml, while the levels of sN-CAD in the sarcoma patients were distributed over a wide range.

Back to article page
\